Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins: Lymphoma trials

The registry lists 36 Lymphoma studies with Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins as lead sponsor. 1 are open to participants now and 18 have results posted.

Early Phase 1 2Phase 1 14Phase 2 19Phase 3 2No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific AntibodiesRecruitingNCT06398457Early Phase 1
• Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived MalignanciesTerminatedNCT03151057Phase 1Results posted
• Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in LymphomaCompletedNCT01665768Phase 2Results posted
• Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic MalignanciesCompletedNCT01203722Phase 1/2Results posted
• Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic CancersTerminatedNCT01135329Phase 2Results posted
• Optimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With Post-transplantation Cy and RituximabTerminatedNCT00946023Phase 2Results posted
• R-ICE and High-Dose Cyclophosphamide With PET/CT for Diffuse Large B-Cell Non-Hodgkin's LymphomaTerminatedNCT00809341Phase 2Results posted
• Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCYCompletedNCT00809276Phase 1/2Results posted
• Safety and Efficacy Study of I-131 Tositumomab in Patients With Relapsed/Refractory Hodgkin's LymphomaCompletedNCT00484874Phase 1/2Results posted
• Vaccine Therapy in Treating Patients Who Have Received First-Line Therapy for Hodgkin's LymphomaTerminatedNCT00478062Phase 1/2Results posted
• Iodine I 131 Tositumomab or Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's LymphomaCompletedNCT00416312Results posted
• Phase 2 Study of Rituximab-ABVD in Classical Hodgkin LymphomaCompletedNCT00369681Phase 2Results posted
• Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's LymphomaCompletedNCT00278161Phase 2Results posted
• Rituximab, Temozolomide, and Methylprednisolone in Treating Patients With Recurrent Primary CNS Non-Hodgkin's LymphomaTerminatedNCT00248534Phase 2Results posted
• Rituximab and Cyclophosphamide Followed by Vaccine Therapy in Treating Patients With Relapsed Hodgkin LymphomaCompletedNCT00134082Phase 1/2Results posted
• Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic CancerCompletedNCT00134017Phase 2Results posted
• Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic CancerCompletedNCT00134004Phase 2Results posted
• Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or LeukemiaCompletedNCT00133991Phase 2Results posted
• Rituximab in Treating Patients With Refractory or Relapsed Primary CNS LymphomaTerminatedNCT00072449Phase 2Results posted
• Resiliency in Older Adults Undergoing Bone Marrow TransplantCompletedNCT04188678
• Nelfinavir for the Treatment of Gammaherpesvirus-Related TumorsTerminatedNCT02080416Early Phase 1
• Study of Rituximab and Brentuximab Vedotin for Relapsed Classical Hodgkin LymphomaTerminatedNCT01900496Phase 1
• Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation CyclophosphamideCompletedNCT01342289Phase 1
• 124I-FIAU Imaging in EBV and KSHV Associated CancersCompletedNCT00982449Not applicable
• Studying Fentanyl in Patients With CancerTerminatedNCT00899951
• Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic CancerCompletedNCT00265837Phase 3
• Cyclophosphamide and/or Mycophenolate Mofetil With or Without Tacrolimus in Treating Patients Who Are Undergoing a Donor Bone Marrow or Peripheral Stem Cell Transplant for Hematologic CancerCompletedNCT00255710Phase 1
• Rituximab, Cyclophosphamide, and G-CSF Followed By Combination Chemotherapy in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant Followed By Rituximab and GM-CSF for Refractory Diffuse Large B-Cell LymphomaCompletedNCT00242996Phase 2
• Fludeoxyglucose F 18 Positron Emission Tomography in Predicting Risk of Relapse in Patients With Non-Hodgkin's Lymphoma Who Are Undergoing Combination Chemotherapy With or Without Autologous Stem Cell or Bone Marrow TransplantCompletedNCT00238368Phase 2
• Cyclophosphamide Plus Bone Marrow Transplantation in Treating Patients With Hematologic CancerCompletedNCT00006042Phase 1
• Azacitidine Plus Phenylbutyrate in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous TreatmentCompletedNCT00005639Phase 1
• Interleukin-2 Following Bone Marrow Transplantation in Treating Patients With Hematologic CancerCompletedNCT00003962Phase 1
• Total-Body Irradiation, Tacrolimus, and Mycophenolate Mofetil Plus Bone Marrow Transplantation in Treating Patients With Hematologic CancersCompletedNCT00003572Phase 2
• Graft-Versus-Host Disease in Treating Patients With Recurrent or Refractory Lymphoma or Hodgkin's DiseaseCompletedNCT00003414Phase 3
• UCN-01 in Treating Patients With Advanced CancerCompletedNCT00003289Phase 1
• Combination Chemotherapy Plus Infusion of White Blood Cells in Treating Patients With Hematologic CancerCompletedNCT00003243Phase 1